Since AML cells resist to NK cell-mediated killing by changing the expression of their surface ligands for various NK cell receptors and these phenotypic defects correlate with clinical outcomes, drugs that are capable of restoring ligand expressions on AML cells can render them more susceptible to NK cell killing [64]. The gene discussed is KLRD1; the disease is acute myeloid leukemia.